Ranibizumab for Neovascularization in Sickle Cell Retinopathy
Status:
Withdrawn
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the ocular and non-ocular safety of a single dose
of ranibizumab in treating neovascularization secondary to sickle cell retinopathy.